AMXT 1501 Dicaprate

PreclinicalSmall molecule

AAminex Therapeutics, Inc.

AMXT 1501 Dicaprate is one of 55 small molecule programs targeting Neuroblastoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeuroblastomaActive, not recruiting

Atypical Teratoid/rhabdoid TumorRecruiting

NeuroblastomaPhase 1/Phase 2

Active, not recruiting

Atypical Teratoid/rhabdoid TumorPreclinical

Recruiting

Competition

Competitive Landscape

237 competitors in Neuroblastoma

#DrugCompanyPhaseTrials

Leukine

Sanofi

Phase 3

18 2

Paraplatin

AAvyxa

Phase 3

38 3

Vepesid

AAvyxa

Phase 3

42 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

54 5

Camptosar

Pfizer

Phase 3

13 6

Tepadina

Alnylam Pharmaceuticals

Phase 3

12 7

Alkeran

AApotex Inc.

Phase 3

28 8

Accutane

CConrado Roberto Hoffmann Filho

Phase 3

28 9

Oncovin

EEastern Cooperative Oncology Group

Oncovin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1/2Recruiting

Advanced Solid Tumors

NCT07287917

Q2 2035

PreclinicalRecruiting

Atypical Teratoid/rhabdoid Tumor

NCT06465199

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Recruiting·AAminex Therapeutics, Inc.·Phase 1/2·NCT07287917·92 enrolled

Atypical Teratoid/Rhabdoid Tumor1 trial

A Phase I/II Study Using Eflornithine (DFMO) and AMXT 1501 for Relapsed and Refractory Neuroblastoma, CNS Tumors, and Sarcomas

Recruiting·MMilton S. Hershey Medical Center·Preclinical·NCT06465199·289 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AMXT 1501 Dicaprate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AMXT 1501 Dicaprate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AMXT 1501 Dicaprate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aminex Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAminex Therapeutics, Inc.

AMXT 1501 Dicaprate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q2 2035

Trials by Indication[1]

Advanced Solid Tumors1 trial

Atypical Teratoid/Rhabdoid Tumor1 trial

References

Drug Info

Quick Facts

Related News